Applied Clinical Trials
Industry news focusing on the people and organizations who work in the clinical trials profession.
Graham Belgrave• As an active member of ICR (Bourne End, UK) for more than 20 years and a clinical research consultant for Ipsen Ltd (Slough, UK), Graham Belgrave has been recognized as the 100th ICR Chartered Scientist.
Megan Sturm
• Praxis (Nashville, TN) has added Megan Sturm to its staff as the new business development manager, where she will oversee the company's activities in its Northeast United States and Southern California areas.
Emma Clayton
• With more than 10 years of conference and exhibition management experience, Emma Clayton has become ICR's (Bourne End, UK) new conference project manager.
• Covance (Princeton, NJ) has made several executive appointments, including Glynis Neagle, MD, as vice president for medical affairs; Robert Bader, PharmD, as director for product safety services; and Thomas Noto as vice president for regulatory affairs.
Glynis Neagle
• Richard Walovitch is WorldCare's (Boston, MA) new chief medical officer. He will bring with him over 20 years of management experience in preclinical and clinical development for therapeutics and diagnostics.
• Hans-Georg Eichler, MD, senior medical officer for the EMEA, has become the first non-U.S. regulatory liaison to the Clinical Trials Transformation Initiative Executive Committee. Dr. Eichler will fill the recently created nonvoting position.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.